The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Role of Reduced Suppression of Glucose Production and Diminished Early Insulin Release in Impaired Glucose Tolerance
Open accessAbstract
BACKGROUND: Insulin resistance and impaired insulin secretion both occur in non-insulin-dependent diabetes (NIDDM), but their relative importance is unclear. Hyperglycemia itself has adverse effects on tissue insulin sensitivity and insulin secretion that make it difficult to distinguish between primary and secondary abnormalities. To avoid this problem we studied subjects with postprandial glucose intolerance but not sustained hyperglycemia. METHODS: We compared the rate of systemic appearance and disappearance of glucose, the output of endogenous hepatic glucose, splanchnic and muscle uptake of glucose, and plasma insulin and glucagon responses after the ingestion of 1 g of glucose per kilogram of body weight in 15 subjects with impaired glucose tolerance (8 of them nonobese and 7 obese) and in 16 normal subjects (9 nonobese and 7 obese) who were matched for age and weight. RESULTS: After glucose ingestion the mean (+/- SE) rate of total systemic appearance of glucose was significantly higher in both the nonobese subjects (455 +/- 12 mmol per five hours) and the obese subjects (486 +/- 17 mmol per five hours) with impaired glucose tolerance than in the respective normal subjects (411 +/- 11 and 436 +/- 7 mmol per five hours). This difference was fully accounted for by the reduced suppression of endogenous hepatic glucose in the subjects with impaired glucose tolerance (a reduction of about 28 percent, vs. 48 percent in the normal subjects; P less than 0.01). Despite late hyperinsulinemia, at 30 minutes the subjects with impaired glucose tolerance had smaller increases in plasma insulin and smaller reductions in plasma glucagon (both P less than 0.01). Molar ratios of plasma insulin to plasma glucagon levels correlated inversely (r = -0.62, P less than 0.001) with the rates of systemic glucose appearance; the latter correlated positively (r = 0.72, P less than 0.0001) with peak plasma glucose concentrations. CONCLUSIONS: Impaired glucose tolerance, the precursor of NIDDM, results primarily from reduced suppression of hepatic glucose output due to abnormal pancreatic islet-cell function. The late hyperinsulinemia may be the consequence of an inadequate early beta-cell response rather than of insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“As indicated by several studies, insulin resistance leads to basal-fasting hyperinsulinemia, which may result in the insensitivity of beta-cell secretion. This insensitivity leads to a lower first-phase insulin secretion to the rising postprandial glucose but a subsequent exaggerated compensatory second-phase insulin secretion, which might result in hypoglycemia [2, 3].”
From Associated Factors with Biochemical Hypoglycemia during an Oral Glucose Tolerance Test in a Chinese Population (2017) · cites this paper as [3]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When the first-phase insulin response decreases, firstly, blood glucose starts to rise after the meal, which leads to late but excessive secretion of the second-phase insulin secretion. Thus, late reactive hypoglycemia occurs.[3]”
From Postprandial Reactive Hypoglycemia (2019) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Indeed, with better matching of subjects for age, sex and obesity, there also does seem to be a decrease of the insulinogenic index in subjects with IGT [5, 87, 88].”
From The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes (2003) · cites this paper as [5]
In the citing paper
“This reduction in the early insulin response results in a lack of adequate suppression of hepatic glucose production with subsequent post challenge hyperglycaemia and increased insulin concentrations late in the test [5, 126].”
From The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes (2003) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coated Charcoal Immunoassay of Insulin
Herbert, V. D., Lau, K., Gottlieb, C. W., & Bleicher, S. J. (1965) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-25-10-1375 · Cited by 2,969
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917
Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes Mellitus
Eriksson, J., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Widén, E., Schalin, C., & Groop, L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210601 · Cited by 807
Rossetti, L., Giaccari, A., & DeFronzo, R. A. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.610 · Cited by 774
Kolterman, O., Gray, R. S., Griffin, J., BURSTEIN, P. J., Insel, J. R., Scarlett, J. A., & Olefsky, J. M. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110350 · Cited by 628
Impaired Glucose Tolerance as a Disorder of Insulin Action
Lillioja, S., Mott, D. M., Howard, B. V., Bennett, P. H., Yki-Järvinen, H., Freymond, D., Nyomba, B. L., Zurlo, F., Swinburn, B., & Bogardus, C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181901 · Cited by 578
METHODS FOR THE INVESTIGATION OF PERIPHERAL BLOOD FLOW
Greenfield, A. D. M., Whitney, R. J., & Mowbray, J. F. (1963) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a070026 · Cited by 494
Andres, R., Cader, G., & Zierler, K. L. (1956) · Journal of Clinical Investigation · doi:10.1172/jci103324 · Cited by 389
Glucagon physiology and pathophysiology in the light of new advances
Unger, R. H. (1985) · Diabetologia · doi:10.1007/bf00281991 · Cited by 361
Research works printed but not linked: 6
- Gerich, 1988, Clin Endocrinol Metab, 2, 307
- Luzi, 1989, Am J Physiol, 257, E241
- 1980, WHO Tech Rep Ser, 646, 1
- Faloona GR, Unger RH. Glucagon. In: Jaffe BM, Behrman HR, eds. Methods of hormone radioimmunoassay. New York: Academic Press, 1974:317–30
- Hetenyi, 1974, Fed Proc, 33, 1841
- Chiasson, 1977, Fed Proc, 36, 229
Cited by
Sorted by citations
Items 201–300 of 593
SİVA, Z. O., Uludüz, D., Keskin, F. E., Erenler, F., Balcı, H., Uygunoğlu, U., Saip, S., Göksan, B., & Sıva, A. (2017) · Cephalalgia · doi:10.1177/0333102417748928 · Cited by 43
β-Cell Death in Diabetes: Past Discoveries, Present Understanding, and Potential Future Advances
Mukherjee, N., Lin, L., Contreras, C., & Templin, A. T. (2021) · Metabolites · doi:10.3390/metabo11110796 · Cited by 44
Metabolic follow-up after long-term pancreas graft survival
Dieterle, C. D., Arbogast, H. P., Illner, W., Schmauss, S., & Landgraf, R. (2007) · European Journal of Endocrinology · doi:10.1530/eje-06-0658 · Cited by 41
Rosenfalck, A. M., Hendel, H. W., Rasmussen, M. H., Almdal, T., Andersen, T., Hilsted, J., & Madsbad, S. (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00161.x · Cited by 41
Surveillance of the liver in type 2 diabetes: important but unfeasible?
Qadri, S. U., & Yki‐Järvinen, H. (2024) · Diabetologia · doi:10.1007/s00125-024-06087-7 · Cited by 45
Preserved direct hepatic insulin action in rats with diet-induced hepatic steatosis
Buettner, R., Ottinger, I., Schölmerich, J., & Bollheimer, L. C. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00453.2003 · Cited by 40
Molecular Concept of Diabetic Wound Healing: Effective Role of Herbal Remedies
Soliman, A. M., Teoh, S. L., Ghafar, N. A., & Das, S. (2018) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557518666181025155204 · Cited by 40
Bakker, S. J. L., Hoogeveen, E. K., Nijpels, G., Kostense, P. J., Dekker, J. M., Gans, R. O. B., & Heine, R. J. (1998) · Diabetologia · doi:10.1007/s001250051047 · Cited by 40
Normal hepatic insulin sensitivity in lean, mild noninsulin-dependent diabetic patients
Pigon, J., Giacca, A., Östenson, C. G., Lam, L., Vranić, M., & Efendić, S. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.10.8855826 · Cited by 41
Yamane, S., Harada, N., Hamasaki, A., Muraoka, A., Joo, E., Suzuki, K., Nasteska, D., Tanaka, D., Ogura, M., Harashima, S., et al. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00143.x · Cited by 39
Watanabe, Y., Nakayama, K., Taniuchi, N., Horai, Y., Kuriyama, C., Ueta, K., Arakawa, K., Senbonmatsu, T., & Shiotani, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116851 · Cited by 39
Kabadi, M. U., & Kabadi, U. M. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90006-9 · Cited by 38
Importance of Postprandial Glucose Levels as a Target for Glycemic Control in Type 2 Diabetes
Tibaldi, J. M. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e318188898e · Cited by 38
Grigorakis, S. I., Alevizaki, M. K., Beis, C., Anastasiou, E., Alevizaki, C. C., & Souvatzoglou, A. (2000) · Gynecologic and Obstetric Investigation · doi:10.1159/000010225 · Cited by 39
Increased glucose production in mice overexpressing human fructose-1,6-bisphosphatase in the liver
Visinoni, S., Fam, B. C., Blair, A. R., Rantzau, C., Lamont, B. J., Bouwman, R. D., Watt, M. J., Proietto, J., Favaloro, J. M., & Andrikopoulos, S. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90552.2008 · Cited by 39
Yi, M., Chen, R. ‐., Yang, R., & Chen, H. (2016) · Diabetic Medicine · doi:10.1111/dme.13174 · Cited by 38
Management of Diabetes in Older Adults
Rizvi, A. A. (2006) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200701000-00005 · Cited by 38
Cozma, L. S., Luzio, S. D., Dunseath, G. J., Langendorg, K. W., Pieber, T. R., & Owens, D. R. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1271 · Cited by 38
Optimizing Insulin Secretagogue Therapy in Patients With Type 2 Diabetes
Schmitz, O., Lund, S. A., Andersen, P. H., Jønler, M., & Pørksen, N. (2002) · Diabetes Care · doi:10.2337/diacare.25.2.342 · Cited by 38
Mechanisms for Hyperglycemia in the Metabolic Syndrome: The Key Role of β‐Cell Dysfunction
Porte, D. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07786.x · Cited by 38
Ahlkvist, L., Vikman, J., Pacini, G., & Åhrén, B. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.06.004 · Cited by 36
Nonsuppressed Glucagon After Glucose Challenge as a Potential Predictor for Glucose Tolerance
Wagner, R. J., Hakaste, L., Ahlqvist, E., Heni, M., Machann, J., Schick, F., OBBERGHEN, E. V., Stefan, N., Gallwitz, B., Tuomilehto, J., et al. (2016) · Diabetes · doi:10.2337/db16-0354 · Cited by 37
Li, J., Tian, H., Li, Q., Wang, N., Wu, T., Liu, Y., Ni, Z., Yu, H., Liang, J., Luo, R., et al. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00638.x · Cited by 37
Acute effects of glucose and insulin on vascular endothelium
Taubert, D., Rosenkranz, A., Berkels, R., Roesen, R., & Sch�mig, E. (2004) · Diabetologia · doi:10.1007/s00125-004-1586-1 · Cited by 37
Ford, S. M., Simon, L., Stouwe, C. V., Allerton, T. D., Mercante, D. E., Byerley, L. O., Dufour, J., Bagby, G. J., Nelson, S., & Molina, P. E. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00142.2016 · Cited by 35
Harada, N., Hamasaki, A., Yamane, S., Muraoka, A., Joo, E., Fujita, K., & Inagaki, N. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00078.x · Cited by 36
The Management of Type 2 Diabetic Patients with Hypoglycaemic Agents
Tsang, M.-W. (2012) · ISRN Endocrinology · doi:10.5402/2012/478120 · Cited by 36
Davies, M. J. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000200 · Cited by 37
Bo, A.-R., & Thorsson, O. (2003) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2002-021547 · Cited by 42
Taniguchi, A., Nakai, Y., Fukushima, M., Imura, H., Kawamura, H., Nagata, I., Florant, G. L., & Tokuyama, K. (1994) · Metabolism · doi:10.1016/0026-0495(94)90119-8 · Cited by 36
Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia
Suppli, M. P., Lund, A., Bagger, J. I., Vilsbøll, T., & Knop, F. K. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2015.10.029 · Cited by 35
Bie, J., Liu, S., Zhou, J., Xu, B., & Shen, Z. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.01.047 · Cited by 35
Meier, J. J., Ueberberg, S., Korbas, S., & Schneider, S. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00315.2010 · Cited by 36
Connexin 36, a key element in pancreatic beta cell function
Pérez-Armendáriz, E. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.015 · Cited by 34
Impaired Glucose-Induced Glucagon Suppression after Partial Pancreatectomy
Schrader, H., Menge, B. A., Breuer, T. G. K., Ritter, P. R., Uhl, W. H., Schmidt, W. E., Holst, J. J., & Meier, J. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0826 · Cited by 36
Hanefeld, M., Monnier, L., Schnell, O., & Owens, D. R. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0153-3 · Cited by 36
Tominaga, A., ISHIZAKI, N., Naruse, Y., Kitakoji, H., & Yamamura, Y. (2011) · Acupuncture in Medicine · doi:10.1136/acupmed-2011-010006 · Cited by 34
The pathophysiological basis for intensive insulin replacement
Rolla, A. R. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802743 · Cited by 35
Toft, I., Bønaa, K. H., Lindal, S., & Jenssen, T. G. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90125-1 · Cited by 34
Haffner, S. M., Miettinen, H., & Stern, M. P. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.5.8626845 · Cited by 34
Insulin resistance and the polycystic ovary syndrome
Hao, G. (2005) · Journal of reproductive medicine · Cited by 33
Diabetes mellitus in patients with infantile cystinosis after renal transplantation
Robert, J., Tête, M.-J., Guest, G., Gagnadoux, M., Niaudet, P., & Broyer, M. (1999) · Pediatric Nephrology · doi:10.1007/s004670050651 · Cited by 32
Standl, E., & Füchtenbusch, M. (2003) · Diabetologia · doi:10.1007/s00125-002-0934-2 · Cited by 32
Physiopathologie du diabète de type 2
Guillausseau, P.-J., & Laloi-Michelin, M. (2003) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(03)00244-3 · Cited by 39
Burned Adults Develop Profound Glucose Intolerance
Rehou, S., Mason, S. A., Burnett, M., & Jeschke, M. G. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001605 · Cited by 31
Saloranta, C., Guitard, C., Pecher, E., de Pablos-Velasco, P. L., Lahti, K., Brunel, P., & Groop, L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2141 · Cited by 31
Liver insulinization as a driver of triglyceride dysmetabolism
Cook, J. R., Hawkins, M. A., & Pajvani, U. B. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00843-6 · Cited by 33
Knop, F. K., Vilsbøll, T., Larsen, S., Madsbad, S., Holst, J. J., & Krarup, T. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.011 · Cited by 29
Demant, M., Bagger, J. I., Suppli, M. P., Lund, A., Gyldenløve, M., Hansen, K. B., Hare, K. J., Christensen, M., Sonne, D. P., Holst, J. J., et al. (2018) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0066 · Cited by 34
A 4-week high-AGE diet does not impair glucose metabolism and vascular function in obese individuals
Linkens, A. M. A., Houben, A. J. H. M., Niessen, P. M. G., Wijckmans, N. E. G., de Goei, E. E. C., den Eynde, M. D. G. V., Scheijen, J. L. J. M., van de Waarenburg, M. P. H., Mari, A., Berendschot, T. T. J. M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.156950 · Cited by 32
Zhang, J., Zheng, Y., Martens, L., & Pfeiffer, A. F. H. (2023) · Nutrients · doi:10.3390/nu15183913 · Cited by 34
Clinical Measures of Islet Function: Usefulness to Characterize Defects in Diabetes
Åhrén, B., Pratley, R. E., Soubt, M., Dunning, B. E., & Foley, J. E. (2008) · Current Diabetes Reviews · doi:10.2174/157339908784220714 · Cited by 30
Early disturbances in insulin secretion in the development of type 2 diabetes mellitus
van Haeften, T. W. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00267-8 · Cited by 30
Matching treatment to pathophysiology in type 2 diabetes
Gerich, J. E. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80017-5 · Cited by 30
Self-citationNagi, D. K., Knowler, W. C., Charles, M.-A. A., Liu, Q. Z., Hanson, R. L., McCance, D. R., Pettitt, D. J., & Bennett, P. H. (1995) · Diabetologia · doi:10.1007/bf00400093 · Cited by 30
Lundqvist, M., Almby, K. E., Wiklund, U., Abrahamsson, N., Kamble, P. G., Pereira, M. J., & Eriksson, J. W. (2020) · Diabetologia · doi:10.1007/s00125-020-05332-z · Cited by 29
Lundqvist, M., Pereira, M. J., Almby, K. E., Hetty, S., & Eriksson, J. W. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad549 · Cited by 29
Repaglinide: a new short‐acting insulinotropic agent for the treatment of Type 2 diabetes
Owens (1999) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1999.00005.x · Cited by 29
Kanauchi, M., Nakajima, M., Saito, Y., & Kanauchi, K. (2003) · Metabolism · doi:10.1053/meta.2003.50078 · Cited by 29
Hussain, R., Shah, M., Iqbal, S., Rehman, W. U., Khan, S., Rasheed, L., Naz, H., Al-Ghulikah, H., Elkaeed, E. B., Pashameah, R. A., et al. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.1023316 · Cited by 29
A review of nateglinide in the management of patients with type 2 diabetes.
Tentolouris, N., Voulgari, C., & Katsilambros, N. L. (2007) · PubMed Central · Cited by 37
Abbasi, S. A., Rahim, F., Hussain, R., Khan, S., Ullah, H., Iqbal, T., Iqbal, N., Khan, H. U., Khan, S., Iqbal, R., et al. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101556 · Cited by 27
Buse, J. B., Polonsky, K. S., & Burant, C. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00031-6 · Cited by 28
König, M., & Holzhütter, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.382069 · Cited by 27
Insulin resistance of gluconeogenic pathways in neonatal rats after prenatal ethanol exposure.
Chen, L., Zhang, T., & Nyomba, B. L. G. (2004) · American Journal of Physiology. Regulatory Integrative and Comparative Physiology · doi:10.1152/ajpregu.00076.2003 · Cited by 34
Riddle, M. C. (1997) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70273-5 · Cited by 27
Pfeffer, F., Nauck, M. A., Benz, S. R., Gwodzinski, A., Zink, R., B�sing, M., Becker, H. D., & Hopt, U. T. (1996) · Diabetologia · doi:10.1007/bf00400678 · Cited by 27
Khedkar, A., Lebovitz, H. E., Fleming, A., Cherrington, A. D., Jose, V. M., Athalye, S. N., & Vishweswaramurthy, A. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.730 · Cited by 26
Molecular Pathways Underlying the Pathogenesis of Pancreatic α-Cell Dysfunction
Kawamori, D., Welters, H. J., & Kulkarni, R. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_18 · Cited by 26
Peripheral and hepatic insulin sensitivity in subjects with impaired glucose tolerance
Berrish, T. S., Hetherington, C., Alberti, K. G. M. M., & Walker, M. (1995) · Diabetologia · doi:10.1007/bf00401842 · Cited by 26
Postprandial Hyperglycemia and Cardiovascular Disease
Gerich, J. E. (2006) · Endocrine Practice · doi:10.4158/ep.12.s1.47 · Cited by 26
Self-citationMechanisms of glucose intolerance during triglyceride infusion
Rigalleau, V., Beylot, M., Pachiaudi, C., Guillot, C., Déléris, G., & Gin, H. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.275.4.e641 · Cited by 26
Insulin resistance in non-insulin-dependent diabetes mellitus
Alzaid, A. (1996) · Acta Diabetologica · doi:10.1007/bf00569416 · Cited by 25
Desai, P., Donovan, L., Janowitz, E., & Kim, J. Y. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s265879 · Cited by 28
Ma, J., Liu, L. Y., Wu, P., Liao, Y., Tao, T., & Liu, W. (2014) · Journal of Diabetes Research · doi:10.1155/2014/294017 · Cited by 27
Mackay, P., Ynddal, L., Andersen, J. V., & McCormack, J. G. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00293.x · Cited by 25
Age-related changes in amylin secretion
Edwards, B. J.-A. (1996) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(95)01664-3 · Cited by 25
Velliquette, R. A., Koletsky, R. J., & Ernsberger, P. R. (2002) · Experimental Biology and Medicine · doi:10.1177/153537020222700303 · Cited by 25
Davies, M. J., Metcalfe, J., Day, J., Grenfell, A., Hales, C. N., & Gray, I. P. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00274.x · Cited by 25
Hata, T., Mera, Y., Kawai, T., Ishii, Y., Kuroki, Y., Kakimoto, K., Ohta, T., & Kakutani, M. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01387.x · Cited by 25
Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus
Gallwitz, B. (2010) · Drug Safety · doi:10.2165/11319130-000000000-00000 · Cited by 24
Screening and design of anti-diabetic compounds sourced from the leaves of neem (Azadirachta indica)
Jalil, A., Ashfaq, U. A., Shahzadi, S., Rasul, I., Rehman, S.-U., Shah, M., & Masoud, M. S. (2013) · Bioinformation · doi:10.6026/97320630091031 · Cited by 24
Lispro administered by the QS-M Needle-Free Jet Injector generates an earlier insulin exposure
Hu, J., Hui, S., Zhao, C., Li, X., Wang, Y., Cheng, Q., Goswami, R., Zhen, Q., Mei, M., Song, Y., et al. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1198772 · Cited by 24
Nosadini, R., Manzato, E., Solini, A., Fioretto, P., Brocco, E., Zambon, S., Morocutti, A., Sambataro, M. P., Velussi, M., Cipollina, M. R., et al. (1994) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1994.tb01083.x · Cited by 24
Aziz, K. M. A. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s54683 · Cited by 23
Kramer, C. K., Chang, Y. R., Hanley, A. J., Connelly, P. W., Sermer, M., Zinman, B., & Retnakaran, R. R. (2015) · Diabetologia · doi:10.1007/s00125-015-3551-6 · Cited by 23
Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients
Voytovich, M. H., Haukereid, C., Hjelmesaeth, J. S., Hartmann, A., Løvik, A., & Jenssen, T. G. (2007) · Clinical Transplantation · doi:10.1111/j.1399-0012.2006.00634.x · Cited by 23
Kruszynska, Y. T., Ghatei, M. A., Bloom, S. R., & McIntyre, N. (1995) · Hepatology · doi:10.1002/hep.1840210408 · Cited by 24
Yang, M., Wei, Y., Liu, J., Wang, Y., & Wang, G. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0537 · Cited by 23
Ji, L., Chan, J. C. N., Yu, M., Yoon, K., Kim, S. G., Choi, S. H., Huang, C., Tu, S., Wang, C., Paldánius, P. M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14205 · Cited by 24
Nakagata, T., Tamura, Y., Kaga, H., Sato, M., Yamasaki, N., Someya, Y., Kadowaki, S., Sugimoto, D., Satoh, H., Kawamori, R., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13423 · Cited by 22
Kaku, K., Kadowaki, T., Terauchi, Y., Okamoto, T., Sato, A., Okuyama, K., Arjona Ferreira, J. C., & Goldstein, B. J. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12507 · Cited by 22
Treatment of non-insulin-dependent diabetes mellitus with metformin.
Guthrie, R. M. (1997) · PubMed · Cited by 22
Can the glyoxylate pathway contribute to fat-induced hepatic insulin resistance?
Song, S. (2000) · Medical Hypotheses · doi:10.1054/mehy.1999.0943 · Cited by 22
Postprandial glycemia and cardiovascular disease in diabetes mellitus
WAJCHENBERG, B. L. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000200010 · Cited by 22
2 Hepatic glucose metabolism and insulin resistance in NIDDM and obesity
Barrett, E. J., & Liu, Z. (1993) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80238-1 · Cited by 22
Khan, I., Rehman, W. U., Rahim, F., Hussain, R., Khan, S., Rasheed, L., Alanazi, A. S., Hefnawy, M., Alanazi, M. M., Shah, S. A. A., et al. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.105078 · Cited by 21
Sakurai, K., Lee, E. Y., Morita, A., Kimura, S., Kawamura, H., Kasamatsu, A., Shiiba, M., Yabe, D., Yokote, K., & Miki, T. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00163.x · Cited by 23
Dahlia, F., Barouagui, S., Hemida, H., Bousaadia, D., & Rahmoune, B. (2020) · South African Journal of Botany · doi:10.1016/j.sajb.2020.04.033 · Cited by 23
Islet cell dysfunction in progression to diabetes mellitus.
Spellman, C. (2007) · PubMed · Cited by 21
Metadata
- Authors
- Mitrakou, A., Kelley, D., Mokan, M., Veneman, T., Pangburn, T., Reilly, J., & Gerich, J.
- Affiliations
- University of Pittsburgh (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1992-01-02
- Volume
- 326
- Issue
- 1
- Pages
- 22-29
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2330273698
- Cited by
- 595
- References
- 47
- Citations by year
- 2026: 12 · 2025: 5 · 2024: 9 · 2023: 11 · 2022: 15 · 2021: 15 · 2020: 13 · 2019: 13 · 2018: 14 · 2017: 20 · 2016: 12 · 2015: 27 · 2014: 25 · 2013: 18 · 2012: 19
- FWCI
- 21.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (7r37dk020411-19)
- National Institute of Diabetes and Digestive and Kidney Diseases (5R37 DK20411)
- National Center for Research Resources (M01RR000056, 5 M01 RR00056)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- impaired glucose tolerance, type 2 diabetes, hepatic glucose production, insulin secretion, hyperinsulinemia, glucagon, insulin/glucagon ratio, muscle glucose uptake, obesity, beta-cell dysfunction, insulin resistance
- MeSH terms
- Insulin Secretion, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucagon, Glucose Tolerance Test, Humans, Insulin, Islets of Langerhans, Liver, Male, Middle Aged, Muscles, Prediabetic State
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
